October 18, 2024

Critical Pathway for rare brain tumor discovered

Critical Pathway for rare brain tumor discovered

Choroid plexus tumors mainly affect toddlers under one year of age. Scientists at the German Cancer Research Center (DKFZ) have now been able to show that a permanently activated important signaling pathway of intracellular communication is responsible for the development of these rare brain tumors.

Crystal Structure of Wnt8
© Kevinmjude/Wikipedia

Tumors of the choroid plexus develop as a result of proliferation of the specialized epithelial cells known to produce the cerebrospinal fluid. Choroid plexus tumors (CPT) are very rare, but are among the most common neoplasms of the central nervous system in infants under one year of age. It is noteworthy that they can already be detected in the third trimester of pregnancy.

CPT can be categorized into the rather benign plexus papillomas and the malignant plexus carcinomas. Choroid plexus papillomas have very good chances of healing, whereas the prognosis for choroid plexus carcinomas is unfavorable. Due to their rarity, these tumors have not been well studied. “It was known that choroid plexus tumors have extensive chromosome defects, but so far no specific cancer-driving mutations have been identified that favor the development of these tumors,” says Annarita Patrizi, a junior research group leader at the DKFZ.

Together with her research group, Patrizi has now presented the results of a comprehensive study of these tumors for the first time. The researchers first compared the gene activity in chroroid plexus tumors and healthy tissue of this brain structure. In the tumors, they found a particularly high number of deviations in components of the so-called Wnt/β-catenin signaling pathway. This important intracellular communication pathway is involved in many processes during embryonic development, for example in organ formation. In adult cells, the signaling pathway is mostly inactive, but in tumor cells it can be reactivated.

Staining of tissue samples from human CPT confirmed that Wnt is constantly activated in the cancer cells. The researchers showed that CPT cells depend on Wnt activity for their survival and growth. If Wnt activity is boosted, this is enough for choroid plexus cells to develop tumor-typical properties such as accelerated proliferation and invasive potential.

Cells in choroid plexus organoids grown in the culture dish are less differentiated when the Wnt inhibitor APC is genetically switched off, thereby enhancing the Wnt signal. They show signs of transformation into tumor cells.

“The constitutive activation of Wnt in the early developmental phases of the choroid plexus apparently leads to a loss of identity of the plexus epithelium, both in mouse and in human organoids. It is conceivable that the normal development of this brain structure depends on the correct spatio-temporal activation of Wnt. Disruptions to the temporal course can impair normal development and lead to tumorigenesis,” explains Patrizi.

Due to its important role in tissue development and homeostasis, the Wnt signaling pathway is an attractive but challenging target for precision oncology. Several clinical trials are currently underway to inhibit this pathway using various strategies. A Wnt inhibitor is currently in phase 1-2 clinical trials for solid tumors.

“We were able to show that this drug inhibits cell proliferation and impairs survival in a CPT cell line,” said Patrizi. “Further research, especially on choroid plexus organoids, should help to finally find targeted treatment options for this disease.”

Hoa Ho K, Trapp M, Guida C, Ivanova EL, De Jaime-Soguero A, Jabali A, Thomas C, Salasova A, Bernatík O, Salio C, Horschitz S, Hasselblatt M, Sassoe-Pognetto M, Čajánek L, Ishikawa H, Schroten H, Schwerk C, Acebrón SP, Angel P, Koch P, Patrizi A.: Activation of Wnt/β-catenin signaling is critical for the tumorigenesis of choroid plexus.
Neuro Oncol. 2024, DOI: 10.1093/neuonc/noae176

Original News

Our latest News

discover more
GENESIS 26 – The LIFE SCIENCE TECH DAY: “The Future Starts Now”

GENESIS 26 – The LIFE SCIENCE TECH DAY: “The Future Starts Now”

Heidelberg, March 13, 2026 – Thursday, March 12, 2026, the boundaries of what is scientifically feasible and technically possible in cancer research were pushed further into the future: The approximately 130 participants at the GENESIS 26 – The LIFE SCIENCE TECH DAY forum hosted by InnovationLab GmbH did not merely content themselves with the scientific […]

Introducing our New Members – Q1 2026

Introducing our New Members – Q1 2026

We are pleased to introduce these new members and highlight the diverse capabilities they bring to our cluster! Looking forward to your active participation! Bioneer A/Shttps://bioneer.dk/Bioneer is an R&D-driven CRO and CDMO and a Danish government-approved RTO with 40 years of experience. The company supports biotech and pharma partners in drug discovery, early development, and […]

Prof. Gudrun Rappold receives medal of honor from the German Society for Human Genetics

Prof. Gudrun Rappold receives medal of honor from the German Society for Human Genetics

Prof. Dr. Gudrun Rappold, senior professor at Heidelberg University’s Medical Faculty, has been awarded the Medal of Honor by the German Society for Human Genetics. The Medal of Honor is the highest award given by the professional association and recognizes outstanding scientific achievements in human genetics as well as special contributions to the advancement of […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp